IBM Estimates Boosted and 4 Stock Analyses Making Headlines Now

International Business Machines Corp. (NYSE:IBM) estimates have been increased by Deutsche Bank raised its estimates for IBM due to expectations regarding the acceleration of near-term hardware growth because of the refreshed mainframe and a POWER7+ server refresh in early October. The firm keeps its Buy rating but increases its price target to $240 on the stock as it believes that the stock is attractively valued at current levels.

Boston Scientific Corporation’s (NYSE:BSX) leadless subcutaneous ICD achieved FDA approval earlier than expected, causing RBC Capital to think that the product may have the ability to help stem share losses by the company’s U.S. ICD business. The firm believes that the new product has the ability to capture nearly 10 percent of the U.S. market during 2014-2015, and it keeps its Outperform rating on the stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): According to RBC Capital, Aveo Pharmaceuticals’ kidney cancer treatment, tivozanib, shows a significantly higher progression free survival rate than its competitors. The firm believes that this data removes a significant overhang, while it continues to recommend buying the stock.

ViroPharma Inc. (NASDAQ:VPHM) target has been raised by JMP Securities due to the firm’s beliefs that the company’s new diversification strategy should significantly reduce its tax rate and create opportunities for the development of new drugs. The firm keeps its Outperform rating on the stock.

Lam Research Corporation (NASDAQ:LRCX) estimates have been reduced by Credit Suisse because of its increased memory exposure and weaker memory capex. The firm keeps its Outperform rating on the stock.

Don’t Miss: Is Coca-Cola’s Stock Split Pullback a Buying Opportunity?